Marcos Palatnik

List of Publications by Year
in descending order

20 papers	1,044 citations	471509 17 h-index	752698 20 g-index
20 all docs	20 docs citations	20 times ranked	868 citing authors

#	Article	IF	Citations
1	A Chimera Containing CD4+ and CD8+ T-Cell Epitopes of the Leishmania donovani Nucleoside Hydrolase (NH36) Optimizes Cross-Protection against Leishmania amazonesis Infection. Frontiers in Immunology, 2017, 8, 100.	4.8	35
2	Leishmania donovani Nucleoside Hydrolase (NH36) Domains Induce T-Cell Cytokine Responses in Human Visceral Leishmaniasis. Frontiers in Immunology, 2017, 8, 227.	4.8	27
3	Cross-Protective Immunity to Leishmania amazonensis is Mediated by CD4+ and CD8+ Epitopes of Leishmania donovani Nucleoside Hydrolase Terminal Domains. Frontiers in Immunology, 2014, 5, 189.	4.8	31
4	Leishmania donovani Nucleoside Hydrolase Terminal Domains in Cross-Protective Immunotherapy Against Leishmania amazonensis Murine Infection. Frontiers in Immunology, 2014, 5, 273.	4.8	22
5	The LeishmuneÂ®Ìs Nucleoside hydrolase DNA vaccine as an aid in immunotherapy of canine visceral leishmaniasis. Procedia in Vaccinology, 2012, 6, 64-73.	0.4	13
6	Resistance to visceral leishmaniasis is severely compromised in mice deficient of bradykinin B2-receptors. Parasites and Vectors, 2012, 5, 261.	2.5	13
7	Adaptive Immunity against Leishmania Nucleoside Hydrolase Maps Its C-Terminal Domain as the Target of the CD4+ T Cellâ€“Driven Protective Response. PLoS Neglected Tropical Diseases, 2010, 4, e866.	3.0	48
8	Decrease of the incidence of human and canine visceral leishmaniasis after dog vaccination with LeishmuneÂ® in Brazilian endemic areas. Vaccine, 2009, 27, 3505-3512.	3.8	91
9	Effective immunotherapy against canine visceral leishmaniasis with the FML-vaccine. Vaccine, 2004, 22, 2234-2243.	3.8	121
10	Improving methods for epidemiological control of canine visceral leishmaniasis based on a mathematical model. Impact on the incidence of the canine and human disease. Anais Da Academia Brasileira De Ciencias, 2004, 76, 583-593.	0.8	35
11	IgG1/IgG2 antibody dichotomy in sera of vaccinated or naturally infected dogs with visceral leishmaniosis. Vaccine, 2003, 21, 2589-2597.	3.8	62
12	Immunotherapy against murine experimental visceral leishmaniasis with the FML-vaccine. Vaccine, 2003, 21, 4668-4676.	3.8	44
13	Saponins, IL12 and BCG adjuvant in the FML-vaccine formulation against murine visceral leishmaniasis. Vaccine, 2002, 21, 30-43.	3.8	98
14	Occurrence of Leishmania donovani parasitemia in plasma of infected hamsters. Acta Tropica, 2001, 80, 69-75.	2.0	16
15	Vaccination of Balb/c mice against experimental visceral leishmaniasis with the GP36 glycoprotein antigen of Leishmania donovani. Vaccine, 2001, 19, 3104-3115.	3.8	43
16	A phase III trial of efficacy of the FML-vaccine against canine kala-azar in an endemic area of Brazil (Sï¿½o) Tj ETQq0 0 0 rgBT /Overlock	3.8	102
17	Vaccination of Swiss Albino mice against experimental visceral leishmaniasis with the FML antigen of Leishmania donovani. Vaccine, 1999, 17, 2554-2561.	3.8	43
18	Haemolytic activities of plant saponins and adjuvants. Effect of Periandra mediterranea saponin on the humoral response to the FML antigen of Leishmania donovani. Vaccine, 1997, 15, 1024-1029.	3.8	84

#	Article	IF	Citations
19	Prevalence of Anti-Leishmania donovani Antibody Among Brazilian Blood Donors and Multiply Transfused Hemodialysis Patients. American Journal of Tropical Medicine and Hygiene, 1997, 57, 168-171.	1.4	67
20	Leishmania donovani: titration of antibodies to the fucose-mannose ligand as an aid in diagnosis and prognosis of visceral leishmaniasis. Transactions of the Royal Society of Tropical Medicine and Hygiene, 1995, 89, 390-393.	1.8	49